SynthesisFrontiers in endocrinology2022
Specific alterations of gut microbiota in diabetic microvascular complications: A systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The gut-eye axis: microbiota and their role in diabetic retinopathy: a systematic review and meta-analysis.BMC ophthalmology · 2026Pooled it
- Causal relationships between the gut microbiota, immune cells, and diabetic kidney disease: a Mendelian randomization and mediation analysis.Renal failure · 2026Article
- Integrated gut microbiota and metabolome signatures revealed by deep metagenomic sequencing in post-stroke cognitive impairment with type 2 diabetes.Microbiology spectrum · 2026Article
- Gut Microbiota and Diabetic Complications: Potential Mechanisms, Microbial Signatures, and Clinical Implications.Microorganisms · 2026Review
- Nutritional methionine restriction modulates gut microbiota and propionate/GPR41 signaling to mitigate diabetic kidney disease.NPJ science of food · 2026Article
- Regulatory mechanisms of Traditional Chinese Medicine on gut microbiota in diabetic microvascular complications.Chinese medicine · 2026Review
- Sex-specific modulation of gut microbiota by empagliflozin contributes to renoprotection in diabetic kidney disease mice.Frontiers in microbiology · 2026Article
- Integrated multi-omics analysis unveils microbiota-metabolite-host interactions and novel biomarkers for early diabetic kidney disease diagnosis.Frontiers in immunology · 2026Article
- From background diabetic retinopathy to its proliferative stage. What is the role of gut microbiota in the trajectory of DR? a Mendelian randomization study with mediation analysis.Diabetology & metabolic syndrome · 2025Article
- Gut Microbiota and Metabolites: Biomarkers and Therapeutic Targets for Diabetes Mellitus and Its Complications.Nutrients · 2025Review
- Urobiome of patients with diabetic kidney disease in different stages is revealed by 2bRAD-M.Journal of translational medicine · 2025Article
- Gut microbiota therapy for chronic kidney disease.Frontiers in immunology · 2025Review
- Modulating the gut microbiota and inflammation is involved in the effect of diosgenin against diabetic nephropathy in rat.Frontiers in pharmacology · 2025Article
- The gut microbiome: a vital link to hyperuricemia, gout and acute flares?Frontiers in endocrinology · 2025Article
- From Gut to Eye: Exploring the Role of Microbiome Imbalance in Ocular Diseases.Journal of clinical medicine · 2024Review
- Advances in the treatment of diabetic peripheral neuropathy by modulating gut microbiota with traditional Chinese medicine.World journal of diabetes · 2024Review
- The Relationship Between Gut Microbiome and Ophthalmologic Diseases: A Comprehensive Review.Cureus · 2024Review
- Advances in fecal microbiota transplantation for the treatment of diabetes mellitus.Frontiers in cellular and infection microbiology · 2024Review
- Causal relationship between T2DM microvascular complications and gut microbiota: a Mendelian randomization study.Frontiers in endocrinology · 2024Article
- Targeting the Gut-Eye Axis: An Emerging Strategy to Face Ocular Diseases.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of gut microbiota in diabetes mellitus (DM) and its complications has been widely accepted. However, the alternation of gut microbiota in diabetic microvascular complications (DC) remains to be determined. Methods: Publications (till August 20 Results: We included 13 studies assessing 329 patients with DC, 232 DM patients without DC, and 241 HC. Compared to DM, patients with DC shared a significantly lower Simpson index (SMD = -0.59, 95% CI [-0.82, -0.36], p < 0.00001), but a higher ACE index (SMD = 0.42, 95% CI[0.11, 0.74], p = 0.009). Compared to HC, DC patients held a lower ACE index (SMD = -0.61, 95% CI[-1.20, -0.02], p = 0.04). The relative abundances of phylum Proteobacteria (SMD = 0.03, 95% CI[0.01, 0.04], p = 0.003, v.s. HC) and genus Conclusions: Gut microbiota perturbations with the depletion of alpha diversity and certain short-chain fatty acids (SCFAs)-producing bacteria were associated with the pathology of DC. Therefore, gut microbiota might serve as a promising approach for the diagnosis and treatment of DC. Further investigations are required to study the mechanisms by which gut dysbiosis acts on the onset and progression of DC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.